Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

A clinician's critique of rheumatoid arthritis health economic models.

Jobanputra P.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv48-iv52. doi: 10.1093/rheumatology/ker246. Review.

PMID:
21859706
2.

[Rheumatoid arthritis: milestones in classification and treatment].

Fiehn C.

Dtsch Med Wochenschr. 2011 Feb;136(5):203-5. doi: 10.1055/s-0031-1272510. Epub 2011 Jan 26. Review. German.

PMID:
21271482
3.

The Sheffield rheumatoid arthritis health economic model.

Tosh J, Brennan A, Wailoo A, Bansback N.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv26-31. doi: 10.1093/rheumatology/ker243.

PMID:
21859702
4.

Health economic issues in rheumatoid arthritis.

Kobelt G.

Scand J Rheumatol. 2006 Nov-Dec;35(6):415-25. Review.

PMID:
17343248
5.

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Z Rheumatol. 2004 Feb;63(1):59-75. German.

PMID:
14991279
6.

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.

Lekander I, Borgström F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF.

Int J Technol Assess Health Care. 2010 Jan;26(1):54-61. doi: 10.1017/S0266462309990596.

PMID:
20059781
7.

Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.

Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A.

Eur J Health Econ. 2010 Feb;11(1):95-104. doi: 10.1007/s10198-009-0205-y. Epub 2009 Dec 5.

PMID:
19967426
9.

Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans.

Barton P.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv32-iv38. doi: 10.1093/rheumatology/ker244.

PMID:
21859704
10.

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, Smolen JS, Aletaha D.

Ann Rheum Dis. 2010 Jun;69(6):995-1003. doi: 10.1136/ard.2009.126714. Epub 2010 May 6. Review.

PMID:
20447950
11.

Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?

Yen JH.

Biomed Pharmacother. 2006 Dec;60(10):688-92. Epub 2006 Oct 10. Review.

PMID:
17049202
12.

Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?

Drummond MF, Barbieri M, Wong JB.

Med Decis Making. 2005 Sep-Oct;25(5):520-33.

PMID:
16160208
13.

Pharmacoeconomics of drug therapy for rheumatoid arthritis.

Tugwell P.

Rheumatology (Oxford). 2000 Jun;39 Suppl 1:43-7. Review.

PMID:
11001379
14.

Comparative effectiveness of treatments for rheumatoid arthritis.

Siegel J.

Ann Intern Med. 2008 Jan 15;148(2):162-3. No abstract available.

PMID:
18195341
15.

[Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].

Kulp W, Greiner W, Graf von der Schulenburg JM.

Pharm Unserer Zeit. 2003;32(5):420-5. Review. German. No abstract available.

PMID:
14526463
16.
17.

Pharmacoeconomics of long-term treatment of rheumatoid arthritis.

Blumenauer B, Coyle D, Tugwell P.

Expert Opin Pharmacother. 2002 Apr;3(4):417-22. Review.

PMID:
11934345
18.
19.

Interest of modelling in rheumatoid arthritis.

Beresniak A, Dupont DM, Becker JC, Merkesdal S.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S96-101. Epub 2012 Oct 18. Review.

PMID:
23078913
20.

Supplemental Content

Support Center